Mantle Cell Lymphoma
From the Journals
NF-kappaB pathway could help solve resistance problem in mantle cell lymphoma
The research could set the stage for therapeutic targets to help avoid drug resistance in mantle cell treatment.
From the Journals
Triple therapy ups response in refractory mantle cell lymphoma
The results show that triple therapy with ibrutinib, lenalidomide, and rituximab should be evaluated in a randomized controlled trial.
From the Journals
VcR-CVAD yields high responses, ‘excellent’ survival in MCL
The moderate-intensity induction and maintenance regimen induced good responses in both younger and older patients.
Conference Coverage
BTK inhibitor zanubrutinib active in non-Hodgkin lymphomas
ATLANTA – Response rates ranged from 31% to 88% depending on the lymphoma subtype.
Conference Coverage
VIDEO - New lymphoma drug approvals: Clinical use, future directions
ATLANTA - At the ASH annual meeting, FDA representatives and clinicians discussed new lymphoma drug approvals and their use in the real-world...
Conference Coverage
VIDEO: Ibrutinib PFS is nearly 3 years in MCL patients who had one prior therapy
ATLANTA – Dr. Simon Rule discusses the implications of the study and how ibrutinib stacks up against other therapies for MCL.
Conference Coverage
Avapritinib yields high response rate in patients with systemic mastocytosis
ATLANTA – Avapritinib was well tolerated in the phase 1 trial, and demonstrated encouraging preliminary activity.
From the Journals
Rituximab key to survival after transplant for mantle cell lymphoma
The benefit of rituximab “stands out, and adds to the increasing body of evidence supporting this practice for all MCL patients after ASCT,...
From the Journals
TP53 mutations could help stratify MCL patients
The study looks at response to standard-of-care regimens in younger patients.
From the Journals
Lenalidomide shows clinical activity in relapsed/refractory MCL
The observational study highlights the potential of the drug in a population of hard-to-treat patients.
News
FDA approves acalabrutinib for second-line treatment of MCL
Approval was based on an 81% overall response rate in a phase 2 trial of 124 patients who had received at least one prior therapy.